A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
Review Will Determine Whether Access To Biogen's SMA Treatment Will Be Expanded
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
You may also be interested in...
It has taken 17 months of negotiations but soon 600-1,200 people in the UK may be able to get Biogen's spinal muscular atrophy therapy now that an access agreement has been inked.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.